Milestone Treatments for Sickle Cell Disease: Bill Morice, M.D., Ph.D.

Answers from the Lab

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the U.S. Food and Drug Administration’s (FDA) recent approval of two gene therapies for sickle cell disease.

Their discussion includes:

  • The cause and characteristics of sickle cell disease.
  • How the new cell-based gene therapies, Casgevy and Lyfgenia, work in the body.
  • Bioethical and accessibility considerations of innovative treatments like gene-editing therapies.
  • A brief update on the status of the FDA’s proposed rule on laboratory-developed tests.

Podcast episode

Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Podcast episode in video format

Answers from the Lab is a Mayo Clinic Laboratories curated podcast sharing knowledge and advancements regarding the state of testing, laboratory science, and the people who make it all happen behind the scenes. 

Information in this post was accurate at the time of its posting.

Luci Gens

Luci Gens is a marketing manager at Mayo Clinic Laboratories. She joined Mayo Clinic in 2022 and has over ten years of experience in hospital-based marketing and communications.